Deutsche Bank AG Cuts Position in Amgen Inc. $AMGN

by · The Markets Daily

Deutsche Bank AG decreased its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 17.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,190,809 shares of the medical research company’s stock after selling 447,421 shares during the quarter. Deutsche Bank AG owned 0.41% of Amgen worth $717,074,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Anfield Capital Management LLC increased its position in shares of Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after acquiring an additional 70 shares during the period. Dogwood Wealth Management LLC increased its position in shares of Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after acquiring an additional 55 shares during the period. Board of the Pension Protection Fund purchased a new stake in shares of Amgen during the fourth quarter worth $26,000. Manning & Napier Advisors LLC increased its position in shares of Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after acquiring an additional 32 shares during the period. Finally, Olistico Wealth LLC purchased a new stake in shares of Amgen during the fourth quarter worth $33,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

NASDAQ:AMGN opened at $344.57 on Wednesday. The firm has a market capitalization of $185.97 billion, a PE ratio of 23.98, a price-to-earnings-growth ratio of 3.47 and a beta of 0.42. The business’s fifty day moving average price is $341.12 and its 200 day moving average price is $345.52. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. Amgen Inc. has a 12 month low of $267.83 and a 12 month high of $391.29.

Amgen (NASDAQ:AMGN – Get Free Report) last posted its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. The firm had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, sell-side analysts anticipate that Amgen Inc. will post 22.38 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.85% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research firms have recently weighed in on AMGN. Freedom Capital raised Amgen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Rothschild & Co Redburn upped their price objective on Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research report on Wednesday, February 18th. Morgan Stanley set a $340.00 price objective on Amgen in a research report on Tuesday. Wall Street Zen lowered Amgen from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Canaccord Genuity Group initiated coverage on Amgen in a research report on Monday, April 20th. They set a “hold” rating and a $366.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $354.12.

Check Out Our Latest Analysis on Amgen

About Amgen

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Further Reading

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).